ASP7663|cas:1190217-35-6|西域试剂

ASP7663,99.16%

产品编号：Bellancom-101907| CAS NO：1190217-35-6| 分子式：C₁₄H₁₄FNO₃| 分子量：263.26

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101907	￥1000.00	杭州北京（现货）
Bellancom-101907	￥1600.00	杭州北京（现货）
Bellancom-101907	￥3000.00	杭州北京（现货）
Bellancom-101907	￥4800.00	杭州北京（现货）
Bellancom-101907	￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ASP7663

产品介绍

ASP7663 是具有口服活性的、选择性的 TRPA1 激动剂。ASP7663 具有抗便秘和抗腹痛的活性。

生物活性

ASP7663 is an orally active and selective TRPA1 agonist. ASP7663 exerts both anti-constipation and anti-abdominal pain actions.

体外研究

ASP7663 concentration dependently increases intracellular Ca²⁺ concentration in human, rat, and mouse TRPA1 expressed in HEK293 cells in a similar manner, with respective EC₅₀ values (95% confidence interval [CI]) of 0.51 (0.40–0.66), 0.54 (0.41–0.72), and 0.50 (0.41–0.63) μmol/L.
ASP7663 concentration-dependently stimulates 5-HT release from QGP-1 cells, a lineage of TRPA1-expressing EC cells, with an EC50 value of 72.5 (52.6–99.9) μmol/L.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ASP7663 significantly improves the loperamide-induced delay in colonic transit in mice.
ASP7663 (orally, 0.3 and 1 mg/kg) significantly shortens the prolonged bead expulsion time caused by loperamide.
ASP7663 (orally, 1 and 3 mg/kg) exhibits inhibitory effects on colorectal distension in rat.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CRD model (colorectal distension in rat).
Dosage:	1 and 3 mg/kg.
Administration:	Orally.
Result:	Significantly reduced the number of abdominal contractions evoked during CRD at pressures of 30, 45, and 60 mmHg. ASP7663 also reduced the number of abdominal contractions by intravenous treatment.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CRD model (colorectal distension in rat).
Dosage:	1 and 3 mg/kg.
Administration:	Orally.
Result:	Significantly reduced the number of abdominal contractions evoked during CRD at pressures of 30, 45, and 60 mmHg. ASP7663 also reduced the number of abdominal contractions by intravenous treatment.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (189.93 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7985 mL	18.9926 mL	37.9853 mL
5 mM	0.7597 mL	3.7985 mL	7.5971 mL
10 mM	0.3799 mL	1.8993 mL	3.7985 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.90 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.90 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明